{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:27:26Z","timestamp":1772292446544,"version":"3.50.1"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T00:00:00Z","timestamp":1317254400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1002206","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T20:41:01Z","timestamp":1317328861000},"page":"e1002206","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["An Integrated Disease\/Pharmacokinetic\/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers"],"prefix":"10.1371","volume":"7","author":[{"given":"Moran","family":"Elishmereni","sequence":"first","affiliation":[]},{"given":"Yuri","family":"Kheifetz","sequence":"additional","affiliation":[]},{"given":"Henrik","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[]},{"given":"Rune Viig","family":"Overgaard","sequence":"additional","affiliation":[]},{"given":"Zvia","family":"Agur","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2011,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology.","volume":"358","author":"OJ Finn","year":"2008","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2007.14.6423","article-title":"Next generation of immunotherapy for melanoma.","volume":"26","author":"JM Kirkwood","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.6004\/jnccn.2006.0058","article-title":"Update on immunotherapy for melanoma.","volume":"4","author":"A Ribas","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1158\/1078-0432.CCR-07-1238","article-title":"Interleukin-21 signaling: functions in cancer and autoimmunity.","volume":"13","author":"ID Davis","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00262-007-0326-z","article-title":"Role of IL-21 in immune-regulation and tumor immunotherapy.","volume":"56","author":"E di Carlo","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nri1688","article-title":"Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation.","volume":"5","author":"WJ Leonard","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1189\/jlb.0308149","article-title":"Interleukin 21: a cytokine\/cytokine receptor system that has come of age.","volume":"84","author":"WJ Leonard","year":"2008","journal-title":"J Leukoc Biol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1399-0039.2009.01382.x","article-title":"IL-21: roles in immunopathology and cancer therapy.","volume":"74","author":"H Sondergaard","year":"2009","journal-title":"Tissue Antigens"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2482","article-title":"Interleukin 21: combination strategies for cancer therapy.","volume":"7","author":"K Skak","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1586\/14737140.6.6.905","article-title":"Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.","volume":"6","author":"BD Curti","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1158\/1078-0432.CCR-08-2663","article-title":"Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.","volume":"15","author":"ID Davis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-07-0410","article-title":"An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.","volume":"13","author":"ID Davis","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1200\/JCO.2007.14.5193","article-title":"Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.","volume":"26","author":"JA Thompson","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1158\/1078-0432.CCR-10-1809","article-title":"Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.","volume":"16","author":"H Schmidt","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14712598.2010.480971","article-title":"Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed\/refractory indolent non-Hodgkin's lymphoma.","volume":"10","author":"MH Hashmi","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-08-1146","article-title":"Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.","volume":"14","author":"S Ansen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/mt.2008.249","article-title":"Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment.","volume":"17","author":"S Kim-Schulze","year":"2009","journal-title":"Mol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1182\/blood-2007-09-113878","article-title":"Angiostatic activity of the anti-tumor cytokine interleukin-21.","volume":"112","author":"K Castermans","year":"2008","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3934\/dcdsb.2004.4.29","article-title":"Hopf point analysis for angiogenesis models.","volume":"4","author":"Z Agur","year":"2004","journal-title":"Discrete and Continuous Dynamics - Series B"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1023841921971","article-title":"A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth.","volume":"5","author":"L Arakelyan","year":"2002","journal-title":"Angiogenesis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/10273660108833067","article-title":"A mathematical tumor model with immune resistance and drug therapy: an optimal control approach.","volume":"3","author":"LG de Pillis","year":"2001","journal-title":"J Theor Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.1998.503","article-title":"The growth law of primary breast cancer as inferred from mammography screening trials data.","volume":"78","author":"D Hart","year":"1998","journal-title":"Br J Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002850050127","article-title":"Modeling immunotherapy of the tumor-immune interaction.","volume":"37","author":"D Kirschner","year":"1998","journal-title":"J Math Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3934\/mbe.2005.2.511","article-title":"Critical-point analysis for three-variable cancer angiogenesis models.","volume":"2","author":"U Forys","year":"2005","journal-title":"Math Biosci Eng"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0025-5564(92)90053-Y","article-title":"A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs.","volume":"109","author":"L Cojocaru","year":"1992","journal-title":"Math Biosci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.bjc.6603310","article-title":"Mathematical models of targeted cancer therapy.","volume":"95","author":"LH Abbott","year":"2006","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0020-7101(84)90026-6","article-title":"Development of optimal drug administration strategies for cancer-chemotherapy in the framework of systems theory.","volume":"15","author":"RS Acharya","year":"1984","journal-title":"Int J Biomed Comput"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1749-6632.1987.tb48738.x","article-title":"The effect of drug schedule to responsiveness of chemotherapy.","volume":"504","author":"Z Agur","year":"1986","journal-title":"Annals NY Acad Sci"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0025-5564(88)90002-8","article-title":"Reduction of cytotoxicity to normal tissues by new regimens of phase-specific drugs.","volume":"92","author":"Z Agur","year":"1988","journal-title":"Mathematical Biosciences"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0959-8049(92)90463-C","article-title":"Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine.","volume":"28A","author":"Z Agur","year":"1992","journal-title":"Eur J Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jtbi.2005.06.037","article-title":"Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.","volume":"238","author":"LG de Pillis","year":"2006","journal-title":"J Theor Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1158\/0008-5472.CAN-08-1723","article-title":"Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.","volume":"68","author":"B Gorelik","year":"2008","journal-title":"Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0025-5564(99)00058-9","article-title":"A mathematical model of cancer treatment by immunotherapy.","volume":"163","author":"F Nani","year":"2000","journal-title":"Math Biosci"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1046\/j.1365-2141.2003.04696.x","article-title":"New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model.","volume":"123","author":"K Skomorovski","year":"2003","journal-title":"Br J Haematol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1051\/mmnp:2008003","article-title":"Improving cancer therapy by doxorubicin and granulocyte colony-stimulating factor: insights from a computerized model of human granulopoiesis.","volume":"1","author":"V Vainstein","year":"2006","journal-title":"Mathematical Modelling of Natural Phenomena"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/1078-0432.CCR-07-1243","article-title":"Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.","volume":"14","author":"JC Panetta","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF03190058","article-title":"Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.","volume":"25","author":"R Gieschke","year":"2000","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1023577514605","article-title":"Pharmacokinetic-pharmacodynamic guided trial design in oncology.","volume":"21","author":"C van Kesteren","year":"2003","journal-title":"Invest New Drugs"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1158\/0008-5472.CAN-06-0241","article-title":"Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model.","volume":"66","author":"A Cappuccio","year":"2006","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jtbi.2007.05.015","article-title":"Optimization of interleukin-21 immunotherapeutic strategies.","volume":"248","author":"A Cappuccio","year":"2007","journal-title":"J Theor Biol"},{"key":"ref41","first-page":"1417","article-title":"Interleukin 21 therapy increases the density of tumor infiltrating CD8(+)T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother.","volume":"56","author":"H Sondergaard","year":"2007"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2307\/3803199","article-title":"Null hypothesis testing: problems, prevalence, and an alternative.","volume":"64","author":"DR Anderson","year":"2000","journal-title":"Journal of wildlife management"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1071\/WR99107","article-title":"Kullback-Leibler information as a basis for strong inference in ecological studies.","volume":"28","author":"KP Burhnham","year":"2001","journal-title":"Wildlife research"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/S0090-9556(24)15049-0","article-title":"Pharmacokinetic models for the saturable distribution of paclitaxel.","volume":"27","author":"MO Karlsson","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2165\/00003088-199732050-00003","article-title":"Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.","volume":"32","author":"SC Piscitelli","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11095-006-9143-x","article-title":"PKPD Model of Interleukin-21 Effects on Thermoregulation in Monkeys-Application and Evaluation of Stochastic Differential Equations.","volume":"24","author":"RV Overgaard","year":"2007","journal-title":"Pharm Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10928-007-9059-z","article-title":"Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.","volume":"34","author":"RV Overgaard","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1145\/321062.321069","article-title":"Direct Search Solution of Numerical and Statistical Problems.","volume":"8","author":"R Hooke","year":"1961","journal-title":"J ACM"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1287\/opre.1060.0320","article-title":"Optimizing chemotherapy scheduling using local search heuristics.","volume":"54","author":"Z Agur","year":"2006","journal-title":"Operations Research"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers.","volume":"222","author":"MA Cheever","year":"2008","journal-title":"Immunol Rev"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.","volume":"111","author":"CS Hinrichs","year":"2008","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/0008-5472.CAN-07-2403","article-title":"Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.","volume":"68","author":"M Marzec","year":"2008","journal-title":"Cancer Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CJI.0b013e3181c0c1cb","article-title":"Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.","volume":"33","author":"H Sondergaard","year":"2010","journal-title":"J Immunother"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.semradonc.2004.01.001","article-title":"Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma.","volume":"14","author":"DI Rosenthal","year":"2004","journal-title":"Semin Radiat Oncol"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T06:48:05Z","timestamp":1741762085000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002206"}},"subtitle":[],"editor":[{"given":"Thomas","family":"Lengauer","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2011,9,29]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1002206","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,29]]}}}